Lösemi tanısı ile takipli çocuk hastalarda COVID-19 enfeksiyonunun değerlendirilmesi

Abstract

Giriş: Koronavirüs hastalığı 2019 (COVID-19), 2019 yılı sonundan itibaren küresel bir sağlık krizine neden olmuştur. Bu çalışmanın amacı, lösemi nedeni ile takipli pediatrik hastalarda COVID-19 hastalığının klinik bulgularını ve tedavi sonuçlarını değerlendirmektir. . Gereç-Yöntem: Şiddetli akut solunum sendromu koronavirüs-2 (SARS-CoV-2) polimeraz zincir reaksiyonu pozitif olan lösemi tanısı ile takipli tüm çocuk ve ergen hastalar çalışmaya dahil edildi. Bulgular: Çalışmaya COVID-19 enfeksiyonu olan toplam 44 lösemi hastası dahil edildi. Primer tanıları açısından değerlendirildiğinde; 36 hasta yeni tanı akut lenfoblastik lösemi (ALL), 4 hasta relaps ALL, 2 hasta refrakter ALL ve 2 hasta akut myeloblastik lösemi idi. Hastaların yaş ortalaması 104±62 aydı. COVID-19 hastaların %11,4'ünde asemptomatik, %84'ünde hafif ve %4,5'inde orta şiddette seyrederken hiçbir hastamızda ciddi enfeksiyon görülmedi. Hiçbir hastamızda ciddi komplikasyon veya ölümde gözlenmemiştir. Sonuç: Çalışmamızda lösemi tanısı ile takipli ve kemoterapi veya immünsüpresif tedavi gören çocuk ve ergenlerde COVID-19'un klinik seyrinin hafif seyrettiği gözlemledik.

Keywords

• Çocuk
• COVID-19
• Lösemi

The severity of COVID-19 infection in children with leukemia

Abstract

Aims: The coronavirus disease 2019 (COVID-19) has been the cause of a global health crisis since the end of 2019. The aim of this study was to evaluate the clinical findings and treatment results of COVID-19 disease in pediatric patients with leukemia. Methods: All the children and adolescents with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive real-time polymerase chain reaction (PCR) and the presence of underlying leukemia were included in the study. Results: A total of 44 leukemia patients with COVID-19 infection were included in the study. Their primary diseases were as follows: 36 patients were newly diagnosed with acute lymphoblastic leukemia (ALL), four patients were relapsed ALL, two patients were refractory ALL, and two patients were acute myeloblastic leukemia. The mean age of patients was 104± 62 months. COVID-19 was asymptomatic in 11.4% of patients, mild in 84%, and moderate in 4.5% whereas none of our patients had a severe infection. No severe complications and/or death were observed in our study group. Conclusion: It has been found that the clinical course of COVID-19 is mild in children and adolescents with leukemia and undergoing chemotherapy or immunosuppressive therapy.

Keywords

• Children
• COVID-19
• Leukemia

References

1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. doi:10.1056/NEJMoa2001017
2. Al-Qahtani AA. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Emergence, history, basic and clinical aspects. Saudi J Biol Sci. 2020;27(10):2531-2538. doi:10.1016/j.sjbs.2020.04.033
3. Kannan S, Shaik Syed Ali P, Sheeza A, Hemalatha K. COVID-19 (Novel Coronavirus 2019) - recent trends. Eur Rev Med Pharmacol Sci. 2020;24(4):2006-2011. doi:10.26355/eurrev_202002_20378
4. Dorantes-Acosta E, Ávila-Montiel D, Klünder-Klünder M, Juárez-Villegas L, Márquez-González H. Survival and complications in pediatric patients with cancer and COVID-19: a meta-analysis. Front Oncol. 2021;10:608282. doi:10.3389/fonc.2020.608282
5. Cuneo A, Scarfò L, Reda G, et al. Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. Blood. 2020;136(6):763-766. doi:10.1182/blood.2020006854
6. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
7. André N, Rouger-Gaudichon J, Brethon B, et al. COVID-19 in pediatric oncology from French pediatric oncology and hematology centers: High risk of severe forms?. Pediatr Blood Cancer. 2020;67(7):e28392. doi:10.1002/pbc.28392
8. Qatawneh MA, Altarawneh M, Alhazaimeh R, et al. Manifestations of COVID-19 infection in children with malignancy: A single-center experience in Jordan. World J Virol. 2022;11(5):321-330. doi:10.5501/wjv.v11.i5.321

9. Freifeld, A.G., E.J. Bow, K.A. Sepkowitz, et al., Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011. 52(4): p. 427-31.
10. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109(6):1088-1095. doi:10.1111/apa.15270
11. Kebudi R, Kurucu N, Tuğcu D, et al. COVID-19 infection in children with cancer and stem cell transplant recipients in Turkey: A nationwide study. Pediatr Blood Cancer. 2021;68(6):e28915. doi:10.1002/pbc.28915
12. Radhakrishnan V, Ovett J, Rajendran A, et al. COVID19 in children with cancer in low- and middle-income countries: Experience from a cancer center in Chennai, India. Pediatr Hematol Oncol. 2021;38(2):161-167. doi:10.1080/08880018.2020.1831113
13. Madhusoodhan PP, Pierro J, Musante J, et al. Characterization of COVID-19 disease in pediatric oncology patients: The New York-New Jersey regional experience. Pediatr Blood Cancer. 2021;68(3):e28843. doi:10.1002/pbc.28843
14. de Rojas T, Pérez-Martínez A, Cela E, et al. COVID-19 infection in children and adolescents with cancer in Madrid. Pediatr Blood Cancer. 2020;67(7):e28397. doi:10.1002/pbc.28397
15. Rouger-Gaudichon J, Thébault E, Félix A, et al. Impact of the first wave of COVID-19 on pediatric oncology and hematology: a report from the French Society of Pediatric Oncology. Cancers (Basel). 2020;12(11):3398. doi:10.3390/cancers12113398
16. Palomo-Collí MÁ, Fuentes-Lugo AD, Cobo-Ovando SR, Juárez-Villegas L. COVID-19 in children and adolescents with cancer from a single center in Mexico City. J Pediatr Hematol Oncol. 2021;43(7):e1047-e1048. doi:10.1097/MPH.0000000000002040
17. Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study [published correction appears in Lancet. 2020 Aug 22;396(10250):534]. Lancet. 2020;395(10241):1919-1926. doi:10.1016/S0140-6736(20)31173-9
18. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145(6):e20200702. doi:10.1542/peds.2020-0702
19. Boulad F, Kamboj M, Bouvier N, Mauguen A, Kung AL. COVID-19 in children with cancer in New York City. JAMA Oncol. 2020;6(9):1459-1460. doi:10.1001/jamaoncol.2020.2028
20. Gampel B, Troullioud Lucas AG, Broglie L, et al. COVID-19 disease in New York City pediatric hematology and oncology patients. Pediatr Blood Cancer. 2020;67(9):e28420. doi:10.1002/pbc.28420
21. Balduzzi A, Brivio E, Rovelli A, et al. Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Estote parati. Bone Marrow Transplant. 2020;55(10):1900-1905. doi:10.1038/s41409-020-0895-4
22. Kebudi R, Chantada G, Kurucu N, Tuğcu D, Mukkada S, C Moreira D. COVID-19: consequences for children with cancer in Turkey and Globally. Turk Arch Pediatr. 2021;56(4):295-299. doi:10.5152/TurkArchPediatr.2021.21134
23. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334-346. doi:10.1056/NEJMoa2021680
24. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory syndrome in children in New York State. N Engl J Med. 2020;383(4):347-358. doi:10.1056/NEJMoa2021756
25. Minotti C, Tirelli F, Barbieri E, Giaquinto C, Donà D. How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? a systematic review. J Infect. 2020;81(1):e61-e66. doi:10.1016/j.jinf.2020.04.026
26. Sepulveda J, Westblade LF, Whittier S, et al. Bacteremia and blood culture utilization during COVID-19 surge in New York City. J Clin Microbiol. 2020;58(8):e00875-20. doi:10.1128/JCM.00875-20